MiRNAs as mediators of drug resistance

Epigenomics

Volumn 4, Issue 4, 2012, Pages 369-381

  Haenisch, Sierk ^a   Cascorbi, Ingolf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

CpG islands; DNA methylation; drug transport; gene silencing; histone acetylation; miRNA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABC TRANSPORTER; ALPHA INTERFERON; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACINOSTAT; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FULVESTRANT; IMATINIB; MICRORNA; MITOMYCIN; MITOXANTRONE; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; VINCRISTINE; VORINOSTAT;

APOPTOSIS; BIOGENESIS; CANCER CHEMOTHERAPY; CELL SURVIVAL; CHROMATIN STRUCTURE; DNA METHYLATION; DNA MODIFICATION; DRUG EFFECT; DRUG RESISTANCE; DRUG RESPONSE; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HISTONE MODIFICATION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TUMOR CELL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICRORNAS;

EID: 84865471981     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.12.39     Document Type: Review

References (97)

1. Szyf M. The early life social environment and DNA methylation: DNA methylation mediating the long-term impact of social environments early in life. Epigenetics 6(8), 971-978 (2011).
2. Lima SC, Hernandez-Vargas H, Herceg Z. Epigenetic signatures in cancer: implications for the control of cancer in the clinic. Curr. Opin. Mol. Ther. 12(3), 316-324 (2010).
3. Pirola L, Balcerczyk A, Okabe J, El-Osta A. Epigenetic phenomena linked to diabetic complications. Nat. Rev. Endocrinol. 6(12), 665-675 (2010).
4. Marques SC, Oliveira CR, Pereira CM, Outeiro TF. Epigenetics in neurodegeneration: a new layer of complexity. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(2), 348-355 (2011).
5. Dong E, Grayson DR, Guidotti A, Costa E. Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation. Epigenomics 1(1), 201-211 (2009).
6. Crea F, Nobili S, Paolicchi E et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist. Updat. 14(6), 280-296 (2011).
7. Starkey Lewis PJ, Dear J, Platt V et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54(5), 1767-1776 (2011).
8. Hashimoto H, Takami Y, Sonoda E et al. Histone H1 null vertebrate cells exhibit altered nucleosome architecture. Nucleic Acids Res. 38(11), 3533-3545 (2010).
9. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 31(1), 27-36 (2010).
10. Kulis M, Esteller M. DNA methylation and cancer. Adv. Genet. 70, 27-56 (2010).
11. Vire E, Brenner C, Deplus R et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078), 871-874 (2006).
12. Sansom OJ, Maddison K, Clarke AR. Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer. Nat. Clin. Pract. Oncol. 4(5), 305-315 (2007).
13. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol. 49, 243-263 (2009). □ Overview of the classification and mechanisms of epigenetic drugs.
14. Suzuki Y, Yanagisawa M, Ariga T, Yu RK. Histone acetylation-mediated glycosyltransferase gene regulation in mouse brain during development. J. Neurochem. 116(5), 874-880 (2011).
15. Gore SD. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat. Clin. Pract. Oncol. 2(Suppl. 1), S30-S35 (2005).
16. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247-1252 (2007).
17. Hrzenjak A, Moinfar F, Kremser ML et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol. Cancer Ther. 5(9), 2203-2210 (2006).
18. Mohammed TA, Holen KD, Jaskula-Sztul R et al. A pilot Phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist 16(6), 835-843 (2011).
19. Scherpereel A, Berghmans T, Lafitte JJ et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A Phase II study. Eur. Respir. J. 37(1), 129-135 (2011).
20. Thomas S, Thurn KT, Bicaku E, Marchion DC, Munster PN. Addition of a histone deacetylase inhibitor redirects tamoxifentreated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res. Treat. 130(2), 437-447 (2011).
21. Sekita S, Yoshihira K, Natori S et al. Mycotoxin production by Chaetomium spp. and related fungi. Can. J. Microbiol. 27(8), 766-772 (1981).
22. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU (VAR) 3-9. Nat. Chem. Biol. 1(3), 143-145 (2005).
23. Chaib H, Nebbioso A, Prebet T et al. Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. Leukemia 26(4), 662-674 (2011).
24. Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett. 585(22), 3549-3554 (2011).
25. Wang J, Lu F, Ren Q et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 71(23), 7238-7249 (2011).
26. Chen Y, Jie W, Yan W, Zhou K, Xiao Y. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy. Crit Rev. Eukaryot. Gene Expr. 22(1), 53-59 (2012).
27. Singh MM, Manton CA, Bhat KP et al. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro. Oncol. 13(8), 894-903 (2011).
28. Racz Z, Kaucsar T, Hamar P. The huge world of small RNAs: regulating networks of microRNAs (review). Acta Physiol Hung. 98(3), 243-251 (2011).
29. Skalsky RL, Cullen BR. Viruses, microRNAs, and host interactions. Annu. Rev. Microbiol. 64, 123-141 (2010).
30. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur. J. Cancer 43(10), 1529-1544 (2007).
31. Eiring AM, Harb JG, Neviani P et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140(5), 652-665 (2010). □ Demonstrates the pleiotropic function of miRNAs. This study describes miRNA that traps the translational regulator poly (rC) - binding protein hnRNP E2 and thereby maintains the translation of CEBPA mRNA.
32. Bao N, Lye KW, Barton MK. MicroRNA binding sites in Arabidopsis class III HD-ZIP mRNAs are required for methylation of the template chromosome. Dev. Cell 7(5), 653-662 (2004).
33. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A codingindependent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465(7301), 1033-1038 (2010). □ Demonstrates the impact of pseudogene mRNAs on miRNA function. A nontranslated mRNA of the pseudogene PTENP1 is reported as acting as a miRNA scavenger and regulates the expression of the tumor suppressor PTEN.
34. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin. Oncol. 38(6), 724-733 (2011).
35. Ferland-McCollough D, Ozanne SE, Siddle K, Willis AE, Bushell M. The involvement of microRNAs in Type 2 diabetes. Biochem. Soc. Trans. 38(6), 1565-1570 (2010).
36. Salta E, De Strooper B. Non-coding RNAs with essential roles in neurodegenerative disorders. Lancet Neurol. 11(2), 189-200 (2012).
37. Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol. Life Sci. 68(10), 1681-1702 (2011).
38. Smits M, Mir SE, Nilsson RJ et al. Downregulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS ONE 6(1), e16282 (2011).
39. Nana-Sinkam SP, Croce CM. Non-coding RNAs in cancer initiation and progression and as novel biomarkers. Mol. Oncol. 5(6), 483-491 (2011).
40. Kovalchuk O, Filkowski J, Meservy J et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 7(7), 2152-2159 (2008).
41. Li Z, Hu S, Wang J et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol. Oncol. 119(1), 125-130 (2010).
42. Zhu H, Wu H, Liu X et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 76(5), 582-588 (2008).
43. Zhang H, Li M, Han Y et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig. Dis. Sci. 55(9), 2545-2551 (2010).
44. Feng DD, Zhang H, Zhang P et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J. Cell Mol. Med. 15(10), 2164-2175 (2011).
45. Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, Yu AM. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem. Pharmacol. 81(6), 783-792 (2011).
46. Liao R, Sun J, Zhang L et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J. Cell Biochem. 104(3), 805-817 (2008).
47. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol. 75(6), 1374-1379 (2009).
48. To KK, Zhan Z, Litman T, Bates SE. Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol. Cell Biol. 28(17), 5147-5161 (2008).
49. To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol. Cancer Ther. 8(10), 2959-2968 (2009).
50. Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet. Genomics 22(3), 198-205 (2012).
51. Liang Z, Wu H, Xia J et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol. 79(6), 817-824 (2010).
52. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int. J. Cancer 127(8), 1785-1794 (2010).
53. *-mediated suppression of SOX2. Cancer Res. 71(9), 3410-3421 (2011). □□ Demonstrates how a deregulated miRNA expression concurrently evokes stemness as well as chemoresistance via induction of ABC transporters in glioma cells.
54. Zhu Y, Yu F, Jiao Y et al. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin. Cancer Res. 17(22), 7105-7115 (2011).
55. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab. Dispos. 37(10), 2112-2117 (2009).
56. Subramanian S, Steer CJ. MicroRNAs as gatekeepers of apoptosis. J. Cell Physiol 223(2), 289-298 (2010).
57. Tomokuni A, Eguchi H, Tomimaru Y et al. miR-146a suppresses the sensitivity to interferon-alpha in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 414(4), 675-680 (2011).
58. Wang ZX, Lu BB, Wang H, Cheng ZX, Yin YM. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch. Med. Res. 42(4), 281-290 (2011).
59. Bai H, Xu R, Cao Z, Wei D, Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 585(2), 402-408 (2011).
60. Gong C, Yao Y, Wang Y et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem. 286(21), 19127-19137 (2011).
61. Tarasov V, Jung P, Verdoodt B et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6(13), 1586-1593 (2007).
62. Zenz T, Mohr J, Eldering E et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 113(16), 3801-3808 (2009).
63. Vogt M, Munding J, Gruner M et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 458(3), 313-322 (2011).
64. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxelresistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70(14), 1501-1512 (2010).
65. le Sage C, Nagel R, Egan DA et al. Regulation of the p27 (Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26(15), 3699-3708 (2007).
66. Miller TE, Ghoshal K, Ramaswamy B et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 283(44), 29897-29903 (2008).
67. Zhao JJ, Lin J, Yang H et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283(45), 31079-31086 (2008).
68. Rao X, Di Leva G, Li M et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30(9), 1082-1097 (2011).
69. Xia L, Zhang D, Du R et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 123(2), 372-379 (2008).
70. Li H, Hui L, Xu W. miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim. Biophys. Sin. (Shanghai) 44(3), 269-277 (2012).
71. Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J. Cancer 127(11), 2520-2529 (2010).
72. Zhu W, Xu H, Zhu D et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother. Pharmacol. 69(3), 723-731 (2012).
73. Zhu W, Zhu D, Lu S et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med. Oncol. 29(1), 384-391 (2012).
74. Gunaratne PH. Embryonic stem cell microRNAs: defining factors in induced pluripotent (iPS) and cancer (CSC) stem cells? Curr. Stem Cell Res. Ther. 4(3), 168-177 (2009).
75. Liu C, Tang DG. MicroRNA regulation of cancer stem cells. Cancer Res. 71(18), 5950-5954 (2011).
76. Yu F, Yao H, Zhu P et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131(6), 1109-1123 (2007).
77. Shimono Y, Zabala M, Cho RW et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138(3), 592-603 (2009).
78. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int. J. Cancer 126(11), 2575-2583 (2010).
79. Choudhry H, Catto JW. Epigenetic regulation of microRNA expression in cancer. Methods Mol. Biol. 676, 165-184 (2011).
80. Rhodes LV, Nitschke AM, Segar HC et al. The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol. Rep. 27(1), 10-16 (2012).
81. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE 6(8), e24099 (2011). □□ Example of a methodological straightforward approach to elucidate the interaction between 5-aza-2'-deoxycytidine and suberoylanilide hydroxamic acid treatment, miR34a expression and regulation of stem cell characteristics in human pancreatic cancer stem cells.
82. Wong KY, Yim RL, So CC, Jin DY, Liang R, Chim CS. Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 118(22), 5901-5904 (2011).
83. Paik JH, Jang JY, Jeon YK et al. MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin. Cancer Res. 17(14), 4761-4771 (2011).
84. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66(3), 1277-1281 (2006).
85. Li X, Liu J, Zhou R, Huang S, Huang S, Chen XM. Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation. Br. J. Haematol. 148(1), 69-79 (2010).
86. Bueno MJ, Pérez de Castro I, Gómez de Cedrón M et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13(6), 496-506 (2008).
87. Ru P, Steele R, Hsueh EC, Ray RB. Anti-miR-203 Upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer 2(7), 720-727 (2011).
88. Zhou R, Yuan P, Wang Y et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34(6), 1395-1405 (2009).
89. Haenisch S, Laechelt S, Bruckmueller H et al. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol. Pharmacol. 80(2), 314-320 (2011).
90. Bao B, Wang Z, Ali S et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. (Phila.) 5(3), 355-364 (2012).
91. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9(10), 775-789 (2010). □ Overview of how miRNAs and miRNA-based therapeutics could enlarge the arsenal of therapy options in cancer.
92. Juergens RA, Wrangle J, Vendetti FP et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1(7), 598-607 (2011).
93. Moskalev EA, Schubert M, Hoheisel JD. RNA-directed epigenomic reprogramming: an emerging principle of a more targeted cancer therapy? Genes Chromosomes. Cancer 51(2), 105-110 (2012).
94. Li Y, Guessous F, Zhang Y et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69(19), 7569-7576 (2009).
95. Yamamura S, Saini S, Majid S et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS ONE 7(1), e29722 (2012).
96. Shi L, Zhang S, Feng K et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int. J. Oncol. 40(1), 119-129 (2012).
97. Li X, Sanda T, Look AT, Novina CD, von Boehmer H. Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J. Exp. Med. 208(4), 663-675 (2011).